RRAD and melanoma: Combination treatment is effective to reduce the viability of melanoma cells – 44% (Rad ×1), 31% (Rad ×2), 4% (Rad ×3), and 0.5% (Rad ×4) versus viability of >95% after four radiations with or without Paclitaxel at a dose rate of 2400 MU/min for normal skin cells (Figure 3A).